Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAT2A | P31153 | 2/20 | 0.38 |
| ▸ | ALDH1A2 | O94788 | 2/20 | 0.38 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.38 |
| ▸ | CDK1 | P06493 | 6/20 | 0.37 |
| ▸ | CNR1 | P21554 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | F9 | P00740 | 1/20 | 0.35 |
| ▸ | GSR | P00390 | 1/20 | 0.35 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4519920 | 0.92 | MAT2A (0.38) | MAT2AALDH1A2ALDH1A3CDK1CNR1 | |
| SCHEMBL4528475 | 0.91 | MAT2A (0.38) | MAT2ACNR1NPC1ALDH1A1GSR | |
| SCHEMBL4522660 | 0.89 | CDK1 (0.39) | CDK1CNR1 | |
| SCHEMBL4516830 | 0.88 | PDE4A (0.42) | MAT2ACNR1ALDH1A1HIF1APDE4A | |
| SCHEMBL4530645 | 0.85 | CNR1 (0.38) | MAT2ACDK1CNR1NPC1ALDH1A1 | |
| SCHEMBL4506865 | 0.84 | CDK1 (0.40) | CDK1 | |
| SCHEMBL4516843 | 0.83 | SRC (0.41) | CDK1CNR1NPC1ALDH1A1HIF1A | |
| SCHEMBL4517600 | 0.82 | CNR1 (0.38) | MAT2ACDK1CNR1NPC1YTHDC1 | |
| SCHEMBL4521275 | 0.80 | ALDH1A3 (0.44) | MAT2AALDH1A2ALDH1A3CDK1CNR1 | |
| SCHEMBL4514724 | 0.80 | CNR1 (0.37) | MAT2ACDK1CNR1NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298856-A1 | 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1) | BROWN REBECCA ELIZABETH | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298856-A1 | 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1) | TRPV1, TRPV2, TRPV4 | MAT2A 3846/4885ALDH1A2 1308/4885ALDH1A3 1238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.